DEF: Intensity Therapeutics Seeks Reverse Split to Stay on Nasdaq

Intensity Therapeutics, Inc. is seeking stockholder approval for a reverse stock split to meet Nasdaq's minimum bid price requirement and improve marketability.

Summary

• A special meeting of stockholders will be held virtually on October 22, 2025, at 10:30 a.m. Eastern time.
• Stockholders will vote on two proposals: 1) an amendment to the Amended and Restated Certificate of Incorporation to effect a reverse stock split of common stock by a ratio of not less than one-for-five and not more than one-for-thirty, with the exact ratio and decision to effect or abandon the split at the board's discretion; and 2) approval to adjourn the Special Meeting if necessary to solicit further proxies for the first proposal.
• The record date for stockholders entitled to vote at the Special Meeting is August 29, 2025.
• The board of directors unanimously recommends a vote FOR both the Amendment Proposal and the Adjournment Proposal.
• As of the record date, there were 49,055,462 shares of common stock outstanding and entitled to vote.
• On June 6, 2025, the company received a letter from Nasdaq notifying it of non-compliance with the $1.00 minimum bid price requirement, as the closing bid price was below $1.00 for 30 consecutive business days.
• The company has until December 3, 2025, to regain compliance with Nasdaq's minimum bid price requirement.
• The closing price for common stock on The Nasdaq Capital Market was $0.3019 per share on August 27, 2025.
• If the reverse stock split is effected, the number of issued and outstanding shares would be reduced to between 9,811,092 shares (1-for-5 split) and 1,635,182 shares (1-for-30 split), assuming no new shares are issued before the effective date.
• No fractional shares will be issued; stockholders entitled to fractional shares will receive a cash payment based on the closing price on the last trading day prior to the split's effective date.
• The reverse stock split is intended to be treated as a recapitalization for U.S. federal income tax purposes, generally not resulting in taxable income, gain, or loss for the company or U.S. Holders, except for cash received in lieu of fractional shares.

Sentiment

Score: 4

Explanation: The filing addresses a critical issue (Nasdaq delisting risk) with a common, but often negatively perceived, solution (reverse stock split). While a necessary step to maintain listing and marketability, it highlights underlying share price weakness and the ongoing need for significant future capital, which carries dilution risk. The board's discretion to abandon the split offers some flexibility, but the overall sentiment reflects a company in a challenging position taking defensive measures.

Positives

• The reverse stock split is a potential means to regain compliance with Nasdaq's $1.00 minimum bid price requirement, preventing delisting.
• Maintaining Nasdaq listing is crucial for market access, liquidity, and investor confidence.
• A higher per-share price may improve marketability to institutional investors and reduce the negative perception associated with low-priced stocks.
• Could attract brokers and analysts who typically avoid lower-priced stocks, potentially increasing trading liquidity.
• The reduction in outstanding shares without reducing authorized shares provides more flexibility for future equity issuances, supporting capital raising activities.

Negatives

• Investors, analysts, and other market participants may hold a negative perception of reverse stock splits.
• The stock prices of some companies that have effected reverse stock splits have subsequently declined, sometimes significantly.
• A reduced number of outstanding shares could adversely affect trading liquidity.
• There are costs associated with implementing a reverse stock split.
• No assurance that the reverse stock split will result in the bid price exceeding or remaining above $1.00, or that it will enable the company to maintain its Nasdaq listing.
• If the market price declines after the reverse stock split, the percentage decline may be greater than without the split.
• The issuance of additional shares from the increased authorized pool would be dilutive to existing stockholders.

Risks

• Failure to regain and maintain Nasdaq's $1.00 minimum bid price requirement could lead to delisting from The Nasdaq Capital Market.
• Delisting would result in trading on OTC Markets or pink sheets, making it more difficult for investors to dispose of shares or obtain accurate price quotations.
• If delisted and the price is below $5.00, shares could be classified as 'penny stock,' imposing additional sales practice requirements on broker-dealers and making trading more difficult and less efficient.
• No assurance that the reverse stock split will increase the market price proportionately or sustain any increase for any period of time.
• Negative investor perception of reverse stock splits could persist or worsen.
• Reduced liquidity due to fewer outstanding shares post-split.
• Dilution of existing stockholders from future equity issuances, which are intended for capital raising activities.
• Inability to secure adequate additional funding when needed could force spending reductions, delays in development programs, or cessation of operations.
• The issuance of authorized but unissued shares could potentially be used as an anti-takeover device, which may not be beneficial to all stockholders.

Future Outlook

The company intends to effect a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement and improve the marketability of its common stock. It also plans to raise substantial additional funding through equity issuances, including via its At the Market Offering Agreement with H.C. Wainwright & Co., LLC, and/or short-term or long-term debt arrangements. There is no assurance that such financing will be available when needed or that the reverse stock split will achieve its desired effects, including a sustained increase in share price or continued Nasdaq listing.

Management Comments

• "We believe hosting a virtual meeting enables greater stockholder attendance and participation from any location around the world, improves meeting efficiency and our ability to communicate effectively with our stockholders, and reduces the cost and environmental impact of the Special Meeting."
• "Our board of directors recommends that stockholders vote FOR the Amendment Proposal and FOR the Adjournment Proposal."
• "Although we presently intend to effect the Reverse Stock Split to regain compliance with The Nasdaq Capital Market’s minimum bid price requirement, our board of directors has reserved the right... to abandon the proposed amendment at any time... before the certificate of amendment is filed with the Secretary of State of the State of Delaware."
• "Our board of directors does not intend to issue any common stock or securities convertible into common stock except on terms that our board of directors deems to be in the best interests of us and our stockholders."

Industry Context

Many small-cap biotechnology companies, particularly those in clinical development without significant revenue, frequently face challenges in maintaining Nasdaq listing requirements due to fluctuating and often declining stock prices. Reverse stock splits are a common strategic maneuver employed by such companies to avoid delisting, maintain access to broader capital markets, and attract institutional investors. The stated need for substantial additional funding is typical for biotech firms in the research and development phase, which often rely on equity or debt financing to advance their pipelines.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Potential for increased share price and continued Nasdaq listing, which could improve market perception and liquidity. However, there are risks of further price decline, reduced liquidity, and dilution from future capital raises. Stockholders entitled to fractional shares will receive cash payments, which are subject to taxes.
• **Employees/Service Providers**: A higher stock price and continued Nasdaq listing could potentially enhance the company's ability to attract and retain talent, though no direct impact is explicitly stated.
• **Creditors**: Successful capital raises, facilitated by maintaining Nasdaq listing, could improve the company's financial stability and ability to meet obligations.

Next Steps

• Stockholders are urged to vote on the Amendment Proposal and Adjournment Proposal at the Special Meeting on October 22, 2025.
• If the Amendment Proposal is approved, the board of directors will determine whether and at what ratio (within the 1-for-5 to 1-for-30 range) to effectuate the Reverse Stock Split.
• If effected, the Reverse Stock Split would become effective upon filing the certificate of amendment with the Secretary of State of the State of Delaware.
• The company expects to file a current report on Form 8-K within four business days after the Special Meeting to publish preliminary or final voting results.
• The company will continue efforts to regain compliance with Nasdaq's $1.00 minimum bid price requirement by December 3, 2025.
• The company intends to raise additional capital through equity issuances and/or debt arrangements.

Key Dates

Recommendation

The proposed reverse stock split is a necessary defensive maneuver to maintain Nasdaq listing and improve market perception, which is crucial for future capital raises. However, it does not address the underlying operational or financial performance that led to the low share price. While avoiding delisting is positive, the inherent risks of reverse splits (potential for further decline, reduced liquidity, and dilution from future capital raises) and the company's ongoing need for substantial funding suggest a 'Hold' position until there is clearer evidence of improved operational performance or successful clinical milestones.

Keywords

Intensity Therapeutics, Reverse Stock Split, Nasdaq Compliance, DEF 14A, Stockholder Meeting, Delisting Risk, Capital Raise, Biotechnology, Share Price, Corporate Governance